

Claims:

1. (Presently amended) A method for treating bronchial inflammatory diseases comprising administering to a patient in need thereof a pharmacologically effective amount Use of a trioxypyrimidine compound having an inhibitory activity against MMP-1, MMP-2, MMP-3, MMP-9 and MMP-14 defined as

- a.) an IC_{50} value of less than $5\mu M$ for MMP-2, MMP-9 and MMP-14 each;
- b.) a ratio of more than 100 for the IC_{50} values of MMP-1:MMP-2, MMP-1:MMP-9, MMP-1:MMP-14; and
- c.) a ratio of more than 10 for the IC_{50} values of MMP-3:MMP-2, MMP-3:MMP-9, MMP-3:MMP-14;

~~for the manufacturing of a medicament for the treatment of bronchial inflammatory diseases in a host mammal in need of such treatment.~~

2. (Presently amended) The method Use according to claim 1, ~~characterized in that~~ wherein said trioxypyrimidine compound is selected from the group consisting of 5-Biphenyl-4-yl-5-[4-(4-nitro-phenyl)-piperazin-1-yl]pyrimidine-2,4,6-trione, 5-(4-Phenoxy-phenyl)-5-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrimidine-2,4,6-trione, 5-[4-(4-Chloro-phenoxy)-phenyl]-5-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrimidine-2,4,6-trione, 5-[4-(3,4-Dichloro-phenoxy)-phenyl]-5-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrimidine-2,4,6-trione, and 5-[4-(4-Bromo-phenoxy)-phenyl]-5-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrimidine-2,4,6-trione.

3. (Presently amended) The method Use according to claim 1 or 2, ~~characterized in that~~ wherein the trioxypyrimidine compound is complexed with water-soluble cyclodextrin.



Appl. No.
Filed:

4.-6. (Canceled).